CEFTAZIDIME FOR INJECTION, BP POWDER FOR SOLUTION

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

CEFTAZIDIME (CEFTAZIDIME PENTAHYDRATE)

제공처:

STERIMAX INC

ATC 코드:

J01DD02

INN (국제 이름):

CEFTAZIDIME

복용량:

3G

약제 형태:

POWDER FOR SOLUTION

구성:

CEFTAZIDIME (CEFTAZIDIME PENTAHYDRATE) 3G

관리 경로:

INTRAVENOUS

패키지 단위:

10X3G

처방전 유형:

Prescription

치료 영역:

THIRD GENERATION CEPHALOSPORINS

제품 요약:

Active ingredient group (AIG) number: 0116900010; AHFS:

승인 상태:

APPROVED

승인 날짜:

2015-04-02

제품 특성 요약

PRODUCT MONOGRAPH
PR
CEFTAZIDIME FOR INJECTION BP
(as ceftazidime pentahydrate)
1 G/VIAL, 2 G/VIAL, 3 G/VIAL, 6 G/VIAL
Sterile Powder for Solution
ANTIBIOTIC
SteriMax Inc.
Date of Revision: February 9, 2018
2770 Portland Drive
Oakville, ON L6H 6R4
Control No.: 212129
_Ceftazidime for Injection BP _
_ _
_Page 2 of 51 _
_ _
PRODUCT MONOGRAPH
PR
CEFTAZIDIME FOR INJECTION BP
(as ceftazidime pentahydrate)
1 G/VIAL, 2 G/VIAL, 3 G/VIAL, 6 G/VIAL
Sterile Powder for Solution
ANTIBIOTIC
CLINICAL PHARMACOLOGY
_In vitro _ studies indicate that the bactericidal action of
ceftazidime, a semisynthetic cephalosporin
antibiotic, results from inhibition of bacterial cell wall synthesis.
Ceftazidime has a high affinity for the Penicillin-Binding Protein-3
(PBP-3) and moderate affinity for the
PBP-1a of certain Gram negative organisms such as _Escherichia _coli
and _Pseudomonas aeruginosa_. The
affinity for PBP-1b is much less than that for either PBP-3 or PBP-1a.
PBP-3 is involved in the process of
cross-wall formation (septation). Binding to this protein results in
formation of filaments and eventual
death of the bacterium. PBP-1a and PBP-1b are involved in longitudinal
wall synthesis (elongation) prior
to septation. Binding to these proteins results in spheroplast
formation followed by rapid lysis.
Ceftazidime has high affinity for PBP-1 and PBP-2 of _ Staphylococcus
aureus_. However, the drug's
affinity for PBP-3 is very much less in this organism.
INDICATIONS AND CLINICAL USE
Ceftazidime for Injection BP may be indicated for the treatment of
patients with infections caused by
susceptible strains of the designated organisms in the following
diseases:
LOWER RESPIRATORY TRACT INFECTIONS
Pneumonia caused by _ Pseudomonas aeruginosa_; _ Haemophilus
influenzae _including ampicillin-resistant
strains; _ Klebsiella _ species; _ Enterobacter _ species; _ Proteus
mirabilis;_ _ Escherichia coli, Serratia _ species,
_Streptococcus pneumoniae_, and _Staphylococcus_ _aureus_ (methicillin
susceptible) strains.
_Ceftazidime for Injection BP _